Fluconazole in transplant recipients: Options and limitations

Transplant Infectious Disease

Volumn 2, Issue 2, 2000, Pages 62-71

  Strahilevitz, J ^a   Sugar, A M ^b   Engelhard, D ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

Antifungal therapy; Fluconazole; Fungal infection; Transplantation

Indexed keywords

AMPHOTERICIN B; CREATININE; CYCLOSPORIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NORTRIPTYLINE; NYSTATIN; PHENYTOIN; RIFABUTIN; RIFAMPICIN; SULFONYLUREA; TACROLIMUS; WARFARIN; ZIDOVUDINE;

CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; PRIORITY JOURNAL; RASH; REVIEW; TRANSPLANTATION;

ANTIFUNGAL AGENTS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; FLUCONAZOLE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS;

EID: 0034061061     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2000.020204.x     Document Type: Review

References (98)

1. HIBBERD PL, RUBIN RH. Clinical aspects of fungal infection in organ transplant recipients (review). Clin Infect Dis 1994 19 (Suppl 1): S33-10.
2. WEY SB, MORI M, PFALLER MA, WOOLSON RF, WENZEL RP. Risk factors for hospital acquired candidemia A matched case-control study. Arch Intern Med 1989: 149: 2349-2353.
3. NAMPOORY MR, KHAN ZU, JOHNY KV, et al. Invasive fungal infections in renal transplant recipients. J Infect 1996: 33: 95-101.
4. COMO JA, DISMUKES WE. Oral azole drugs as systemic antifungal therapy. N Engl J Med 1994: 330: 263-272.
5. GOA KL, BARRADELL LB. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs 1995: 50: 658-690.
6. WINGARD JR, MERZ WG, RINALDI MG, JOHNSON TR, KARP JE, SARAL R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991: 325: 1274-1277.
7. MARR KA, WHITE TC, VAN BURIK JA, BOWDEN RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis 1997: 25: 908-910.
8. FORTUN J, LOFEZ SAN ROMAN A, et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 1997: 16: 314-318.
9. REX JH, PFALLER MA, GALGIANI JN, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997: 24: 235-247.
10. PFALLER MA, REX JH, RINALDI MG. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin Infect Dis 1997: 24: 776-784.
11. EL-YAZIGI A, ELLIS M, ERNST P, HUSSEIN R, BAILLIE FJ. Effect of repeated dosing on the pharmacokinetics of oral fluconazole in bone marrow transplant patients. J Clin Pharmacol 1997: 37: 1031-1037.
12. OSOWSKI CL, DIX SP, LIN LS, MULLINS RE, GELLER RB, WINGARD JR. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. Transplantation 1996: 61: 1268-1272.
13. ASSAN R, FREDJ G, LARGER E, FEUTREN G, BISMUTH H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab 1994: 20: 49-52.
14. GRANINGER W, PRESTERIL E, SCHNEEWEISS B, TELEKI B, GEORGOPOULOS A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993: 26: 133-146.
15. REX JH, BENNETT JE, SUGAR AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 1994: 331: 1325-1330.
16. ANAISSIE EJ, DAROUICHE RO, ABI-SAID D, et al. Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 1996: 23: 964-972.
17. KUJATH P, LERCH K, KOCHENDORFER P, Boos C. Comparative study of the efficacy of fluconazole versus amphotericin B/flucytosine in surgical patients with systemic mycoses. Infection 1993: 21: 376-382.
18. GRANINGER W, PRESTERIL E, SCHNEEWEISS B, TELEKY B, GEORGOPOULOS A. Treatment of Candida albicans fungaemia with fluconazole. J Infect 1993: 26: 133-146.
19. CONTI DJ, TOLKOFF-RUBIN NE, BAKER GP Jr, et al. Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation 1989: 48: 692-695.
20. VAN'T WOUT JW, MATTIE H, VAN FURTH R. A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. J Antimicrob Chemother 1988: 21: 665-672.
21. KRCMERY V Jr, KUNOVA A, MARDIAK J. Nosocomial Cryptococcus laurentii fungemia in a bone marrow transplant patient after prophylaxis with ketoconazole successfully treated with oral fluconazole [letter]. Infection 1997: 25: 130.
22. SINGH N, GAYOWSKI T, MARINO IR. Successful treatment of disseminated cryptococcosis in a liver transplant recipient with fluconazole and flucytosine, an all oral regimen. Transplant Int 1998: 11: 63-65.
23. HOLT CD, WINSTON DJ, KUBAK B, et al. Coccidioidomycosis in liver transplant patients. Clin Infect Dis 1997: 24: 216-221.
24. TAN HP, WAHLSTROM HE, ZAMORA JU, HASSANEIN T. Aureobasidium pneumonia in a post liver transplant recipient: a case report Hepatogastroenterology 1997: 44: 1215-1218.
25. HORBER FF, LERUT JP, REICHEN J, ZIMMERMANN A, JAEGER P, MALINVERNI R. Visceral leishmaniasis after orthotopic liver transplantation, impact of persistent splenomegaly. Transpl Int 1993: 6: 55-57.
26. EDWARDS JE Jr, BODEY GP, BOWDEN RA, et al. International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections. Clin Infect Dis 1997: 25: 43-59.
27. FRICK T, FRYD DS, GOODALE RL, SIMMONS RL, SUTHERLAND DE, NAJARIAN JS. Incidence and treatment of candida esophagitis in patients undergoing renal transplantation. Data from the Minnesota prospective randomized trial of cyclosporine versus antilymphocyte globulin-azathioprine. Am J Surg 1988: 155: 311-333.
28. DAROUICHE RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998: 26: 259-272.
29. REX JH, RINALDI MG, PFALLER MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995: 39: 1-8.
30. SANGUINETI A, CARMICHAEL JK, CAMPBELL K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch Intern Med 1993: 153: 1122-1124.
31. ENGELHARD D. Bacterial and fungal infections in children undergoing bone marrow transplantation. Bone Marrow Transplant 1998: 21 (Suppl 2): S78-80.
32. WEINBERGER M, SACKS T, SULKES J, SHAPIRO M, POLACHECK I. Increasing fungal isolation from clinical specimens: experience in a university hospital over a decade. J Hosp Infect 1997: 35: 185-195.
33. ENGELHARD D, POLACHECK I, NAPARSTEK E, et al. Candidemia in bone marrow transplantation - A 14 year prospective study. Trends in invasive fungal infections 4. November 5-8, 1997 Barcelona, Spain (abstract P-46).
34. ELISHOOV H, OR R, STRAUSS N, ENGELHARD D. Nosocomial colonization, septicemia, and Hickman/Broviac catheter-related infections in bone marrow transplant recipients. A 5-year prospective study. Medicine (Baltimore) 1998: 77: 83-101.
35. GOODMAN JL, WINSTON DJ, GREENFIELD RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992: 326: 845-851.
36. SLAVIN MA, OSBORNE B, ADAMS R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995: 171: 1545-1552.
37. MENICHETTI F, DEL FAVERO A, MARTINO P, et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. The GIMEMA Infection Program. Ann Intern Med 1994: 120: 913-918.
38. WINGARD JR, MERZ WG, RINALDI MG, MILLER CB, KARP JE, SARAL R. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 1993: 37: 1847-1849.
39. EPSTEIN JB, RANSIER A, LUNN R, CHIN E, JACOBSON JJ, LE N, REECE D. Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996: 81: 291-296.
40. DRAKOS PE, NAGLER A, OR R, et al. Invasive fungal sinusitis in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1993: 12: 203-208.
41. KUSNE S, DUMMER JS, SINGH N, et al. Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) 1988: 67: 132-143.
42. PAYA CV, HERMANS PE, WASHINGTON JA II, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 1989: 64: 555-564.
43. WAJSZCZUK CP, DUMMER JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985: 40: 347-353.
44. CASTALDO P, STRATTA RJ, WOOD RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991: 126: 149-156.
45. COLLINS LA, SAMORE MH, ROBERTS MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994: 170: 644-652.
46. BRIEGEL J, FORST H, SPILL B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995: 14: 375-382.
47. PATEL R, PORTELA D, BADLEY AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996: 62: 926-934
48. WINSTON DJ, EMMANOUILIDES C, BUSUTTIL RW. Infections in liver transplant recipients (review). Clin Infect Dis 1995: 21: 1077-1089.
49. GLADDY RA, RICHARDSON SE, DAVIES HD, SUPERINA RA. Candida infection in pediatric liver transplant recipients. Liver Transpl Surg 1999: 5: 16-24.
50. SCHIMPFF SC, GREENE WH, YOUNG VM, et al. Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med 1975: 82: 351-358.
51. GORENSEK MJ, CAREY WD, WASHINGTON JA II, VOGT DP, BROUGHAM TA, WESTVEER MK. Selective bowel decontamination with quinolones and nystatin reduces gram-negative and fungal infections in orthotopic liver transplant recipients. Cleve Clin J Med 1993: 60: 139-144.
52. KUNG N, FISHER N, GUNSON B, HASTINGS M, MUTIMER D. Fluconazole prophylaxis for high-risk liver transplant recipients (letter). Lancet 1995: 345: 1234-1245.
53. DECRUYENAERE J, COLARDYN F, VOGELAERS D, et al. Combined use of fluconazole and selective digestive decontamination in the prevention of fungal infection after adult liver transplantation. Transplant Proc 1995: 27: 3515-3516.
54. VIVLANI MA, TORTORANO AM, MALASPINA C, et al Surveillance and treatment of liver transplant recipients for candidiasis and aspergillosis. Eur J Epidemiol 1992: 8: 433-436.
55. LUMBRERAS C, CUERVAS-MONS V, JARA P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996: 174: 583-588.
56. WINSTON DJ, PAKRASI A, BUSUTTIL RW. Prophilactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial Ann Intern Med 1999: 131: 729-737.
57. WINGARD JR, MERZ WG, RINALDI MG, JOHNSON TR, KARP JE, SARAL R. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991: 325: 1274-1277.
58. FORTUN J, LOPEZ-SAN ROMAN A, VELASCO JJ, et al. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur J Clin Microbiol Infect Dis 1997: 16: 314-318.
59. KRALOVIC SM, RHODES JC. Phaeohyphomycosis caused by Dactylaria (human dactylariosis): report of a case with review of the literature. J Infect 1995: 31: 107-113.
60. JACOBS F, BYL B, BOURGEOIS N, et al. Trichoderma viride infection in a liver transplant recipient. Mycoses 1992: 35: 301-303.
61. SNYDMAN DR, WERNER BG, HEINZE-LACEY B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987: 317: 1049-1054.
62. CHUGH KS, SAKHUJA V, JAIN S, et al. High mortality in systemic fungal infections following renal transplantation in third-world countries. Nephrol Dial Transplant 1993: 8: 168-172.
63. RUBIN RH, WOLFSON JS, COSMI AB, TOLKOFF-RUBIN NE. Infection in the renal transplant recipient. Am J Med 1981: 70: 405-411.
64. MARTINEZ-MARCOS F, CISNEROS J, GENTIL M, et al. Prospective study of renal transplant infections in 50 consecutive patients. Eur J Clin Microbiol Infect Dis 1994: 13: 1023-1028.
65. ANONYMOUS. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. Working party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 1993: 32: 5-21.
66. HIBBERD PL, RUBIN RH. Clinical aspects of fungal infection in organ transplant recipients Clin Infect Dis 1994: 19 (Suppl 1): S33-40.
67. EDWARDS JE. Candida species. In: MANDELL GL, BENNETT JE, DOLIN R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases (4th edn) New York: Churchill Livingstone, 1995: 2289-2306.
68. LEU HS, HUANG CT. Clearance of funguria with short-course antifungal regimens: a prospective, randomized, controlled study. Clin Infect Dis 1995: 20: 1152-1157.
69. FAN-HAVARD P, O'DONOVAN C, SMITH SM, OH J, BAMBERGER M, ENG RH. Oral fluconazole versus amphotericin B bladder irrigation for treatment of candidal funguria. Clin Infect Dis 1995: 21: 960-965.
70. JACOBS LG, SKIDMORE EA, FREEMAN K, LIPSCHULTZ D, Fox N. Oral fluconazole compared with bladder irrigation with amphotericin B for treatment of fungal urinary tract infections in elderly patients. Clin Infect Dis 1996: 22: 30-35.
71. KANJ SS, WELTY-WOLF K, MADDEN J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996: 75: 142-156.
72. KRAMER MR, MARSHALL SE, STARNES VA, GAMBERG P, AMITAI Z, THEODORE J. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med 1993: 153: 2010-2016.
73. DOWLING RD, BALADI N, ZENATI M, et al. Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg 1990: 49: 118-122.
74. FLUME PA, EGAN TM, PARADOWSKI LJ, DETTERBECK FC, THOMPSON JT, YANKASKAS JR. Infectious complications of lung transplantation. Impact of cystic fibrosis. Am J Respir Crit Care Med 1994: 149: 1601-1607.
75. DUMMER JS, MONTERO CG, GRIFFITH BP, HARDESTY RL, PARADIS IL, Ho M. Infections in heart-lung transplant recipients. Transplantation 1986: 41: 725-729.
76. BERTOCCHI M, THEVENET F, BASTIEN O, et al. Fungal infections in lung transplant recipients. Transplant Proc 1995: 27: 1695.
77. REICHENSPURNER H, GAMBERG P, NITSCHKE M, et al. Significant reduction in the number of fungal infections after lung, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997: 29: 627-628.
78. CALVO V, BORRO JM, MORALES P, et al. Antifungal prophylaxis during the early postoperative period of lung transplantation. Valencia Lung Transplant Group Chest 1999: 115: 1301-1304.
79. WAIN JC, WRIGHT CD, RYAN DP, ZORB SL, MATHISEN DJ, GINNS LC. Induction immunosuppression for lung transplantation with OKT3. Ann Thorac Surg 1999: 67: 187-193.
80. HORVATH J, DUMMER S, LOYD J, WALKER B, MERRILL WH, FRIST WH. Infection in the transplanted and native lung after single lung transplantation. Chest 1993: 104: 681-685.
81. DUMMER JS, BAHNSON HT, GRIFFITH BP, HARDESTY RL, THOMPSON ME, Ho M. Infections in patients on cyclosporine and prednisone following cardiac transplantation. Transplant Proc 1983: 15 (Suppl 1): 2779-2781.
82. HUMMEL M, THALMANN U, JAUTZKE G, STAIB F, SEIBOLD M, HETZER R. Fungal infections following heart transplantation. Mycoses 1992: 35: 23-34.
83. MENAFOGLIO A, COMETTA A, BERGUER DG, et al. Infectious complications in cardiac transplantation: Lausanne experience. Schweiz Med Wochenschr 1994: 124: 1479-1488.
84. WASER M, MAGGIORINI M, LUTHY A, et al. Infectious complications in 100 consecutive heart transplant recipients. Eur J Clin Microbiol Infect Dis 1994: 13: 12-18.
85. HOFFLIN JM, POTASMAN I, BALDWIN JC, OYER PE, STINSON EB, REMINGTON JS. Infectious complications in heart transplant recipients receiving cyclosporine and orticosteroids. Ann Intern Med 1987: 106: 209-216.
86. ARGENZIANO M, CATANESE KA, MOAZAMI N, et al. The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 1997: 16: 822-831.
87. MCCARTHY PM, SCHMITT SK, VARGO RL, GORDON S, KEYS TF, HOBBS RE. Implantable LVAD infections: implications for permanent use of the device. Ann Thorac Surg 1996: 61: 359-365.
88. FISCHER SA, TRENHOLME GM, COSTANZO MR, PICCIONE W. Infectious complications in left ventricular assist device recipients. Clin Infect Dis 1997: 24: 18-23.
89. SPRINGER WE, WASLER A, RADOVANCEVIC B, et al. Retrospective analysis of infection in patients undergoing support with left ventricular assist systems. ASAIO J 1996: 42: M763-65.
90. HERRMANN M, WEYAND M, GEESHAKE B, et al. Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation. Circulation 1997: 95: 814-817.
91. GOLDSTEIN DJ, EL-AMIR NG, ASHTON RC Jr, et al. Fungal infections in left ventricular assist device recipients. Incidence, prophylaxis, and treatment. ASAIO J 1995: 41: 873-875.
92. LUMBRERAS C, FERNANDEZ I, VELOSA J, MUNN S, STERIOFF S, PAYA CV. Infectious complications following pancreatic transplantation: incidence, microbiological and clinical characteristics, and outcome. Clin Infect Dis 1995: 20: 514-520.
93. PERKINS JD, FROHNERT PP, SERVICE FJ, et al. Pancreas transplantation at Mayo: III. Multidisciplinary management. Mayo Clin Proc 1990: 65: 496-508.
94. EVERETT JE, WAHOFF DC, STATZ C, et al. Characterization and impact of wound infection after pancreas transplantation. Arch Surg 1994: 129: 1310-1316.
95. BENEDETTI E, GRUESSNER AC, TROPPMANN C, et al. Intra-abdominal fungal infections after pancreatic transplantation: incidence, treatment, and outcome. J Am Coll Surg 1996: 183: 307-316.
96. STRATTA RJ. Ganciclovir/acyclovir and fluconazole prophylaxis after simultaneous kidney-pancreas transplantation. Transplant Proc 1998: 30: 262.
97. ARIAS-DIAZ J, VARA E, RABADAN PM, et al. Efficacy of amphotericin B and fluconazole in removal of fungus contamination from human islet cultures: effects on hormone secretion. Transplant Proc 1994: 26: 599-602.
98. SUGAR AM, HITCHCOCK CA, TROKE PF, PICARD M. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob Agents Chemother 1995: 39: 598-601.